| News

Bottneuro advancing personalized Alzheimer’s therapy

02.11.2021

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient’s brain are stimulated. In order to determine the correct areas of the brain for treatment, the spin-off from the University of Basel has turned to the imaging processes developed by Positrigo.

Three co-founders of Bottneuro: Bekim Osmani, Tino Töpper and Alois C. Hopf (img: Bottneuro)

One approach to treating Alzheimer’s disease is to eliminate substances that cause the disease by stimulating specific areas of the brain. This is the strategy being pursued by the startup Bottneuro, a spin-off from the University of Basel based at Technologiepark Basel. The company intends to establish a network of diagnostic centers for Alzheimer’s patients to offer personalized therapy approaches to those affected by the disease. The business magazine Forbes listed Bottneuro among the 30 best spin-offs situated in the German-speaking DACH (Germany, Austria and Switzerland) region to keep an eye on over the course of 2021.

For the development of its personalized therapy, Bottneuro is joining forces with Positrigo. The spin-off from the Swiss Federal Institute of Technology Zurich (ETH) specializes in the development of nuclear medicine imaging technologies. Bottneuro is planning to use a positron emission tomography (PET) device developed by Positrigo to accurately localize the correct areas of the brain to treat in Alzheimer’s patients.

The two startups have signed a Memorandum of Understanding (MoU) for the delivery of several NeuroLF-type brain PET imaging devices, Positrigo writes in a press release. These are to be delivered as soon as a CE mark is awarded to the NeuroLF. “We are delighted to agree this cooperation with Positrigo”, comments Bekim Osmani, Managing Director of Bottneuro, in the press release. “The NeuroLF brain PET device will enable us to offer cost-effective PET scans in our Alzheimer’s diagnostic centers in order to obtain important 3D data sets that we need for our personalized Alzheimer’s therapy”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

EsoCap impresses investors
Basel Area Business & Innovation, Innovation, Invest

EsoCap impresses investors

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors...

Read More
Plug and Play settles in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Plug and Play settles in the Basel Area

Plug and Play is coming to the canton of Basel-Landschaft. The first founding partner of the innovation promoter from Silicon...

Read More
Bachem builds its largest production building
Basel Area Business & Innovation, Innovation, Invest

Bachem builds its largest production building

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of...

Read More
Bottneuro advancing personalized Alzheimer’s therapy
Basel Area Business & Innovation, Innovation, Invest

Bottneuro advancing personalized Alzheimer’s therapy

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of...

Read More
Straumann plans to build innovation center in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Straumann plans to build innovation center in the Basel Area

The Basel-based dental specialist Straumann is planning to construct a new technology and innovation center in Arlesheim in the canton...

Read More
Ontotext opens new office in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Ontotext opens new office in the Basel Area

Ontotext, a company based in New York City and the Bulgarian capital of Sofia, has opened a new location at...

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.